Activity Overview
As recently as a decade ago, it was unusual for a patient with cystic fibrosis (CF) to survive past childhood. However, aggressive and improved pharmacological and nonpharmacological treatments have increased the median survival age from approximately 25 years in 1985 to almost 37 years in 2005. With increasing survival comes a new level of complexity in caring for the emerging adult (18–25 years old), including but not limited to the transition of care from pediatrics to adulthood. To optimize patient outcomes, an understanding of disease intervention by age and strategies for compliance and adherence are necessary to decrease the number of hospitalizations, emergency department visits, and the need for frequent intravenous antibiotic therapy to extend survival time, decrease morbidity, enhance quality of life, and decrease mortality in patients suffering from CF.

Goal
This educational activity will provide physicians with an update on the clinical use of cystic fibrosis (CF) therapies as recommended in the CF Pulmonary Guidelines to optimize patient care and develop strategies for improving treatment adherence and compliance for emerging adults (aged 18–25 years old).

Target Audience
This activity is designed for pediatric pulmonologists, pulmonologists, geneticists, and primary care physicians. No prerequisites required.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Evaluate current and emerging therapies and the delivery mechanism of these therapies.
• Recognize and identify adherence issues in patients with cystic fibrosis.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

CME Information
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

After reviewing this webcast activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.

Release date: December 31, 2008. Expiration date: December 31, 2010.

Estimated time to complete activity: 1 hour 15 minutes.

Activity Format
Webcast 1.25 AMA PRA Category 1 Credits. A Summary of the Cystic Fibrosis Foundation Guidelines will be provided for each participant.

Faculty
Michael P. Boyle, MD, FCCP
Associate Professor of Medicine
Director, The Johns Hopkins Adult Cystic Fibrosis Program
The Johns Hopkins University School of Medicine
Baltimore, MD

John Paul Clancy, MD
Professor, Director, and Raymond K. Lyrene Chair in Pediatric Pulmonology
The Children’s Hospital of Alabama
University of Alabama at Birmingham
Birmingham, AL

Kristin A. Riekert, PhD
Assistant Professor
Co-Director, The Johns Hopkins Adherence Research Center
Division of Pulmonary and Critical Care Medicine
The Johns Hopkins University
Baltimore, MD

Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

Dr Boyle reports having no financial or advisory relationships with corporate organizations related to this activity.

Dr Clancy reports having no financial or advisory relationships with corporate organizations related to this activity.

Dr Riekert reports receiving grants/research support from Genentech, Inc. and Novartis Pharmaceuticals Corporation.

Off-Label Product Discussion:
No speaker has indicated that their presentation will include information on off-label products.

Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Internet CME Policy
The Office of Continuing Medical Education (CME) at The Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at The Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of The Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.